Biogen Inc. (BIIB)

280.19
11.84 4.41
NASDAQ : Health Technology
Prev Close 268.35
Open 294.32
Day Low/High 278.17 / 294.99
52 Wk Low/High 215.78 / 374.99
Volume 3.25M
Avg Volume 1.79M
Exchange NASDAQ
Shares Outstanding 163.19M
Market Cap 44.03B
EPS 31.50
P/E Ratio 8.34
Div & Yield N.A. (N.A)
Two ETFs to Play a Bounce Back in Biotech

Two ETFs to Play a Bounce Back in Biotech

The lack of major drug launches last year, along with disappointing quarterly results, dragged down biotech stocks last year but they could soon be headed higher.

Jim Cramer Says Take a Long Term View on Healthcare Stocks

Jim Cramer Says Take a Long Term View on Healthcare Stocks

Jim Cramer says healthcare companies will be in the spotlight this week and investors should take a long term view of the sector if the stocks selloff.

Biogen's Chart Shows Shares Could Turn Bullish

Biogen's Chart Shows Shares Could Turn Bullish

Is the biotech company's stock on its way higher?

Biogen's Chart Could Turn Bullish

Biogen's Chart Could Turn Bullish

The stock may be on its way higher.

Midday Report: U.S. Stocks Slip; Biogen Jumps on Higher Drug Sales

Midday Report: U.S. Stocks Slip; Biogen Jumps on Higher Drug Sales

Stocks remained lower as poor earnings reports from industry giants Apple (AAPL) and Boeing (BA) punished the tech and industrials sectors.

Biogen: No Cure In Sight For Slow Growth

Biogen: No Cure In Sight For Slow Growth

BIIB needs to announce some top-line suprises when it reports on Wednesday to spark investor enthusiasm.

Europe Markets Shrug Off China Stock Selloff, Oil at 11-Year Lows

Europe Markets Shrug Off China Stock Selloff, Oil at 11-Year Lows

European markets appear to have shrugged-off China's selloff overnight which ended the trading session with a five percent decline.

Immunotherapy, Genomics Gains Make These ‘Lucky Years’ Says David Agus

Immunotherapy, Genomics Gains Make These ‘Lucky Years’ Says David Agus

Sky-high drug prices and rising insurance premiums are grabbing the daily headlines.

Jim Cramer Says General Mills Still a Stock to Hold for the Long Term

Jim Cramer Says General Mills Still a Stock to Hold for the Long Term

General Mills (GIS) is a still a stock to hold for the long term, even as the company missed on earnings due to a slump in cereal sales, says Cramer.

Coach, Facebook Shares Trending Well into 2016 Says BTIG Strategist

Coach, Facebook Shares Trending Well into 2016 Says BTIG Strategist

Shares of Coach (COH) are down 12% so far this year, but have surged 13% in the past month.

Biogen's Chart Shows an Improving Condition

Biogen's Chart Shows an Improving Condition

BIIB's action since late November has been constructive. 

My Top 5 Picks From Jim Cramer's List of 'Anointed' Stocks for 2016

My Top 5 Picks From Jim Cramer's List of 'Anointed' Stocks for 2016

I chose stocks that I believe present the best investment opportunity right now.

My 5 Picks From Cramer's 'Anointed' Stocks

My 5 Picks From Cramer's 'Anointed' Stocks

I picked the stocks that I believe present the best investment opportunity right now.

Cramer: Hey, Don't Leave the Table!

Cramer: Hey, Don't Leave the Table!

There are more bad cards in the deck than good ones right now, but that's no reason to quit the game.

Making Sense of a Rugged Day

Making Sense of a Rugged Day

Let's break it down into several components.

Cramer: Fretting Over the Fed? Go Shopping

Cramer: Fretting Over the Fed? Go Shopping

Whether it's winter coats or stocks, you have reasons for buying.

Warren Buffett Is Satisfied With IBM, but Jim Cramer Wants More

Warren Buffett Is Satisfied With IBM, but Jim Cramer Wants More

Warren Buffett is satisfied with his IBM holdings, but is Jim Cramer satisfied with the stock? Not exactly.

Don't Abandon the Biotech Ship

Don't Abandon the Biotech Ship

There's too much good out there.

The Market Crushes the Bears Once Again

The Market Crushes the Bears Once Again

What a difference a week makes.

Ailing Stocks Are Making a Recovery

Ailing Stocks Are Making a Recovery

Apple tops the list, but it has lots of company.

Jim Cramer Wants to Buy Bank of America After Friday's Jobs Report

Jim Cramer Wants to Buy Bank of America After Friday's Jobs Report

Jim Cramer, TheStreet’s Action Alerts PLUS Portfolio Manager and host of CNBC’s ‘Mad Money,’ said he wants to buy more Bank of America(BAC) shares on a pullback.

Jim Cramer Says Investors Should Own These 3 Stocks in November

Jim Cramer Says Investors Should Own These 3 Stocks in November

TheStreet's Jim Cramer says that while the markets will end October in the green, there's a lot of weakness across many sectors. These are the 3 stocks to own.

Jim Cramer Says Hold Allergan, as it May Not Take First Bid From Pfizer

Jim Cramer Says Hold Allergan, as it May Not Take First Bid From Pfizer

Jim Cramer, The Street's Action Alerts PLUS Portfolio Manager and host of CNBC's 'Mad Money,' said Allergan (AGN) is a stock to hold onto.

No Easy Cure for What Ails Biotech Stocks

No Easy Cure for What Ails Biotech Stocks

Make incremental moves until the onslaught in the space is over.

No Easy Cure for What Ails Biotech Stocks

No Easy Cure for What Ails Biotech Stocks

Meanwhile, make incremental moves until the onslaught in the space is over.

What to Watch Wednesday: Will Coca Cola's Earnings Fizzle?

What to Watch Wednesday: Will Coca Cola's Earnings Fizzle?

For Wednesday October 21, TheStreet awaits quarterly results from Coca Cola (KO), Boeing (BA), General Motors (GM), Biogen (BIIB), American Express (AXP), Kinder Morgan (KMI), eBay (EBAY) and more.

Jim Cramer Says Buy General Electric and Seagate Technology

Jim Cramer Says Buy General Electric and Seagate Technology

Jim Cramer answered viewers' social media questions on the floor of the New York Stock Exchange Friday and explained why investors should own stock of General Electric (GE).

Grasping at Growth: The Hunt Is On

Grasping at Growth: The Hunt Is On

Once again, buyers are going for the gusto.

Biogen Takes a Turn for the Worse; but a Bullish Divergence Keeps Us on Watch

Biogen Takes a Turn for the Worse; but a Bullish Divergence Keeps Us on Watch

Price action did not go our way, as the On-Balance-Volume line failed to turn higher.

5 Biotech Stocks With Bullish Charts That Will Push the Sector Higher

5 Biotech Stocks With Bullish Charts That Will Push the Sector Higher

The common thread in these 5 names is the bullish divergence between the lower lows in price and the higher low in the momentum study.